Stuart Flanagan

Title: Innovations by Inventor Stuart Flanagan

Introduction

Stuart Flanagan is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit factor XIa for the treatment of thromboembolic diseases. With a total of 6 patents to his name, Flanagan's work is recognized for its potential impact on medical therapies.

Latest Patents

Flanagan's latest patents include innovative compounds designed to address thromboembolic diseases. One of his notable inventions is titled "Substituted pyrrolidines as factor XIa inhibitors for the treatment of thromboembolic diseases." This invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof, which are effective inhibitors of factor XIa. Another significant patent is "Pyrimidinone and its derivatives inhibiting factor XIa," which also presents compounds of the general formula (I) that serve as inhibitors of factor XIa, useful in the prevention and therapy of thromboembolic diseases.

Career Highlights

Stuart Flanagan is currently associated with Ono Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical sector. His work focuses on developing new therapeutic options that can significantly improve patient outcomes in the treatment of thromboembolic conditions.

Collaborations

Flanagan collaborates with esteemed colleagues such as Steve Courtney and Chris Yarnold, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Stuart Flanagan's contributions to the field of pharmaceuticals through his patents and collaborations highlight his commitment to advancing medical science. His work in developing factor XIa inhibitors is paving the way for new treatments in thromboembolic diseases.